{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:14:07Z","timestamp":1781889247373,"version":"3.54.5"},"reference-count":164,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Beh\u00e7et\u2019s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage. The aim of this review is to provide current data on how innovations in clinical evaluation, investigations and treatments were able to improve the prognosis of uveitis associated with BD.<\/jats:p>","DOI":"10.3390\/jcm10112318","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T10:30:32Z","timestamp":1622025032000},"page":"2318","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Old and New Challenges in Uveitis Associated with Beh\u00e7et\u2019s Disease"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8592-3810","authenticated-orcid":false,"given":"Julie","family":"Gueudry","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, H\u00f4pital Charles Nicolle, F-76000 Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Leclercq","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Charles Nicolle, F-76000 Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de R\u00e9f\u00e9rences Maladies Autoimmunes et Syst\u00e9miques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, F-75013 Paris, France"},{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France"},{"name":"Biotherapy (CIC-BTi), H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, AP-HP, F-75651 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current concepts in the etiology and treatment of Behcet disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Surv. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"495s","DOI":"10.1016\/S0248-8663(02)00665-3","article-title":"Interferons and Behcet\u2019s disease","volume":"23","author":"Wechsler","year":"2002","journal-title":"Rev. Med. Interne"},{"key":"ref_3","first-page":"529","article-title":"Ocular manifestations of Behcet\u2019s disease","volume":"150","author":"Cassoux","year":"1999","journal-title":"Ann. Med. Interne"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et\u2019s disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.revmed.2013.12.005","article-title":"Epidemiology of Beh\u00e7et\u2019s disease","volume":"35","author":"Mahr","year":"2014","journal-title":"Rev. Med. Interne"},{"key":"ref_6","first-page":"239","article-title":"Behcet\u2019s disease","volume":"55","author":"Wechsler","year":"2005","journal-title":"Rev. Prat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s13023-020-01620-4","article-title":"French recommendations for the management of Beh\u00e7et\u2019s disease","volume":"16","author":"Barete","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12969-016-0070-z","article-title":"Beh\u00e7et\u2019s disease in children, an overview","volume":"14","year":"2016","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/archopht.1970.00990040453009","article-title":"The rate of visual loss in Beh\u00e7et\u2019s disease","volume":"84","author":"Mamo","year":"1970","journal-title":"Arch. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: An analysis of 880 patients","volume":"138","author":"Onal","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/09273948.2012.713159","article-title":"Comparison of presenting features and three-year disease course in Turkish patients with Beh\u00e7et uveitis who presented in the early 1990s and the early 2000s","volume":"20","author":"Cingu","year":"2012","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.revmed.2018.02.022","article-title":"Ocular manifestations in Beh\u00e7et\u2019s disease","volume":"39","author":"Desbois","year":"2018","journal-title":"Rev. Med. Interne"},{"key":"ref_13","first-page":"808","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000074113","article-title":"Review of the chronology of clinical manifestations in 60 patients with Beh\u00e7et\u2019s disease","volume":"207","author":"Alpsoy","year":"2003","journal-title":"Dermatology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Criteria for diagnosis of Behcet\u2019s disease (1990). International Study Group for Behcet\u2019s Disease. Lancet, 335, 1078\u20131080.","DOI":"10.1016\/0140-6736(90)92643-V"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3349\/ymj.1997.38.6.365","article-title":"Diagnostic criteria of Beh\u00e7et\u2019s disease: Problems and suggestions","volume":"38","author":"Lee","year":"1997","journal-title":"Yonsei Med. J."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"(2014). The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J. Eur. Acad. Dermatol. Venereol., 28, 338\u2013347.","DOI":"10.1111\/jdv.12107"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09273948.2012.723112","article-title":"Epidemiology of Beh\u00e7et disease","volume":"20","author":"Khairallah","year":"2012","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/09273948.2013.795228","article-title":"Differential diagnosis of Beh\u00e7et Uveitis","volume":"21","author":"Gupta","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ajo.2014.11.029","article-title":"Nonglaucomatous localized retinal nerve fiber layer defects in Beh\u00e7et uveitis","volume":"159","author":"Oray","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/eye.2014.138","article-title":"Long-term efficacy of infliximab on background vascular leakage in patients with Beh\u00e7et\u2019s disease","volume":"28","author":"Keino","year":"2014","journal-title":"Eye"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/09273948.2016.1205100","article-title":"Review for Diagnostics of the Year: Multimodal Imaging in Beh\u00e7et Uveitis","volume":"25","author":"Ozdal","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MD.0b013e318211bf28","article-title":"Beh\u00e7et disease: Evolution of clinical manifestations","volume":"90","author":"Ideguchi","year":"2011","journal-title":"Medicine"},{"key":"ref_24","first-page":"225","article-title":"The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behcet\u2019s disease in Japan: Ophthalmologic aspects","volume":"77","author":"Mishima","year":"1979","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","article-title":"Behcet\u2019s disease: Ocular effects and treatment","volume":"27","author":"Deuter","year":"2008","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Tugal-Tutkun, I., Onal, S., Stanford, M., Akman, M., Twisk, J.W.R., Boers, M., Oray, M., \u00d6zdal, P., Kadayifcilar, S., and Amer, R. (2020). An Algorithm for the Diagnosis of Beh\u00e7et Disease Uveitis in Adults. Ocul. Immunol. Inflamm., 1\u201310.","DOI":"10.1080\/09273948.2020.1736310"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1167\/iovs.18-24348","article-title":"Outer Plexiform Layer Elevations as a Marker for Prior Ocular Attacks in Patients With Behcet\u2019s Disease","volume":"59","author":"Kido","year":"2018","journal-title":"Investig. Ophtalmol. Vis. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8612","DOI":"10.1038\/s41598-019-45149-4","article-title":"Association between subfoveal choroidal thickness and leakage site on fluorescein angiography in Beh\u00e7et\u2019s uveitis","volume":"9","author":"Shirahama","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/IAE.0000000000001587","article-title":"Quantitative analysis of structural alterations in the choroid of patients with active Beh\u00e7et Uveitis","volume":"38","author":"Onal","year":"2018","journal-title":"Retina"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/09273948.2019.1612452","article-title":"Optical Coherence Tomography Angiography Findings in Active and Inactive Ocular Beh\u00e7et Disease","volume":"28","author":"Accorinti","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1097\/IAE.0000000000001418","article-title":"Optical coherence tomography angiography in patients with Beh\u00e7et Uveitis","volume":"37","author":"Khairallah","year":"2017","journal-title":"Retina"},{"key":"ref_32","first-page":"2180723","article-title":"Assessment of Vascular Change Using Swept-Source Optical Coherence Tomography Angiography: A New Theory Explains Central Visual Loss in Behcet\u2019s Disease","volume":"2017","author":"Somkijrungroj","year":"2017","journal-title":"J. Ophtalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40942-018-0117-z","article-title":"Comparison between optical coherence tomography angiography and fluorescein angiography findings in retinal vasculitis","volume":"4","author":"Torricelli","year":"2018","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/IAE.0000000000002177","article-title":"optical coherence tomography angiography findings in patients with nonocular Beh\u00e7et disease","volume":"39","author":"Raafat","year":"2019","journal-title":"Retina"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/iovs.62.3.8","article-title":"Parafoveal Microvascular Alterations in Ocular and Non-Ocular Beh\u00e7et\u2019s Disease Evaluated With Optical Coherence Tomography Angiography","volume":"62","author":"Smid","year":"2021","journal-title":"Investig. Ophtalmol. Vis. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s10792-018-1059-z","article-title":"Quantitative analysis of retinal microcirculation in optical coherence tomography angiography in cases with Beh\u00e7et\u2019s disease without ocular involvement","volume":"39","year":"2019","journal-title":"Int. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Pei, M., Zhao, C., Gao, F., Qu, Y., Liang, A., Xiao, J., and Zhang, M. (2019). Analysis of Parafoveal Microvascular Abnormalities in Behcet\u2019s Uveitis Using Projection-Resolved Optical Coherence Tomographic Angiography. Ocul. Immunol. Inflamm., 1\u20136.","DOI":"10.1080\/09273948.2019.1685108"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Karalezli, A., Kaderli, S.T., Sul, S., and Pektas, S.D. (2020). Preclinical ocular features in patients with Beh\u00e7et\u2019s disease detected by optical coherence tomography angiography. Eye, 1\u20138.","DOI":"10.1038\/s41433-020-01294-z"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/09273948.2019.1635167","article-title":"Comparison of Optical Coherence Tomography Angiography Findings in Patients with Beh\u00e7et\u2019s Disease and Healthy Controls","volume":"28","author":"Koca","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1869-5760-3-30","article-title":"Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis","volume":"3","author":"Leder","year":"2013","journal-title":"J. Ophtalmic Inflamm. Infect."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/09273948.2019.1605264","article-title":"Ultra-Wide-Field Imaging in Uveitis","volume":"27","author":"Cunningham","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/IAE.0000000000000197","article-title":"Use of ultra-wide-field retinal imaging in the management of active Beh\u00e7et retinal vasculitis","volume":"34","author":"Mesquida","year":"2014","journal-title":"Retina"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00417-008-0823-6","article-title":"Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Beh\u00e7et uveitis","volume":"246","author":"Kir","year":"2008","journal-title":"Graefe Arch. Clin. Exp. Ophtalmol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/09273948.2013.866257","article-title":"Therapy of ocular Beh\u00e7et disease","volume":"22","author":"Zierhut","year":"2014","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14712598.2019.1595578","article-title":"Expert opinion on the use of biological therapy in non-infectious uveitis","volume":"19","author":"Touhami","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Behcet\u2019s syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet\u2019s disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"ref_48","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine A in Behcet\u2019s syndrome","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transpl. Proc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet\u2019s syndrome: A single masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br. J. Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.1780280611","article-title":"Effectiveness of cyclosporin therapy for Behcet\u2019s disease","volume":"28","author":"Nussenblatt","year":"1985","journal-title":"Arthritis Rheum."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1034\/j.1600-0420.1998.760118.x","article-title":"Cyclosporin-A therapy in severe uveitis of Behcet\u2019s disease","volume":"76","author":"Sullu","year":"1998","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"372s","DOI":"10.1016\/j.transproceed.2004.01.003","article-title":"Experience with cyclosporine in endogenous uveitis posterior","volume":"36","author":"Hesselink","year":"2004","journal-title":"Transpl. Proc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/1756-185X.12139","article-title":"Methotrexate in ocular manifestations of Behcet\u2019s disease: A longitudinal study up to 15 years","volume":"16","author":"Davatchi","year":"2013","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/14728214.2020.1847271","article-title":"Beh\u00e7et\u2019s disease uveitis: Is there a need for new emerging drugs?","volume":"25","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(94)92549-6","article-title":"Interferon-alpha 2b for refractory ocular Behcet\u2019s disease","volume":"343","author":"Feron","year":"1994","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","article-title":"Treatment of ocular symptoms of Behcet\u2019s disease with interferon alpha 2a: A pilot study","volume":"82","author":"Kotter","year":"1998","journal-title":"Br. J. Ophthalmol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-0420.1997.tb00638.x","article-title":"Interferon alpha for ocular Behcet\u2019s disease","volume":"75","author":"Accorinti","year":"1997","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: A retrospective monocentric study of 45 patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/kem199","article-title":"Efficacy and safety of interferon-\u03b1 in the treatment of corticodependent uveitis of paediatric Behcet\u2019s disease","volume":"46","author":"Berger","year":"2007","journal-title":"Rheumatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Behcet disease: Review of the literature","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Behcet uveitis","volume":"244","author":"Urgancioglu","year":"2006","journal-title":"Graefe Arch. Clin. Exp. Ophtalmol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","article-title":"Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet\u2019s disease","volume":"8","author":"Wechsler","year":"2000","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et disease: A randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis","volume":"129","author":"Onal","year":"2011","journal-title":"Arch. Ophthalmol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","article-title":"Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Beh\u00e7et disease","volume":"146","author":"Gueudry","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","article-title":"Long-term Efficacy of Interferon in Severe Uveitis Associated with Beh\u00e7et Disease","volume":"25","author":"Diwo","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Behcet\u2019s disease with sight threatening posterior or panuveitis","volume":"87","author":"Kotter","year":"2003","journal-title":"Br. J. Ophthalmol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/annrheumdis-2014-205571","article-title":"Pegylated interferon-\u03b1-2b reduces corticosteroid requirement in patients with Beh\u00e7et\u2019s disease with upregulation of circulating regulatory T cells and reduction of Th17","volume":"74","author":"Lightman","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/09273948.2017.1332768","article-title":"Long-Term Efficacy of Pegylated Interferon Alpha-2b in Beh\u00e7et\u2019s Uveitis: A Small Case Series","volume":"27","author":"Celiker","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_71","first-page":"599","article-title":"Potential of Pegylated Interferon Alpha-2a in Beh\u00e7et Uveitis: A Report of Five Cases","volume":"24","author":"Bielefeld","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_72","first-page":"503","article-title":"The use of interferon-alpha in Beh\u00e7et\u2019s disease\u2014Review of the literature and possible mechanisms of action","volume":"528","author":"Treusch","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/bjophthalmol-2019-314154","article-title":"Biologic therapy for Beh\u00e7et\u2019s uveitis: A systematic review","volume":"104","author":"Uke","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"102481","DOI":"10.1016\/j.jaut.2020.102481","article-title":"Comparison of conventional immunosuppressive drugs versus anti-TNF-\u03b1 agents in non-infectious non-anterior uveitis","volume":"113","author":"Leclercq","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Behcet\u2019s disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF Agents for Behcet\u2019s Disease: Analysis of Published Data on 369 Patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet\u2019s disease: A comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","article-title":"Management of major organ involvement of Beh\u00e7et\u2019s syndrome: A systematic review for update of the EULAR recommendations","volume":"57","author":"Ozguler","year":"2018","journal-title":"Rheumatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","article-title":"Adalimumab therapy for refractory uveitis: A pilot study","volume":"24","author":"Salom","year":"2008","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/jop.2008.0073","article-title":"Adalimumab therapy for refractory uveitis: A pilot study","volume":"24","author":"Serrano","year":"2008","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_82","first-page":"565","article-title":"Adalimumab: A new modality for Behcet\u2019s disease?","volume":"66","author":"Missotten","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/09273948.2010.483314","article-title":"Clinical experience with adalimumab in the treatment of ocular Behcet disease","volume":"18","author":"Bawazeer","year":"2010","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kunimi, K., Usui, Y., Asakage, M., Maehara, C., Tsubota, K., Mitsuhashi, R., Umazume, A., Kezuka, T., Sakai, J.I., and Goto, H. (2020). Anti-TNF-\u03b1 Therapy for Refractory Uveitis Associated with Beh\u00e7et\u2019s Syndrome and Sarcoidosis: A Single Center Study of 131 Patients. Ocul. Immunol. Inflamm., 1\u20138.","DOI":"10.1080\/09273948.2020.1791346"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10787-020-00697-4","article-title":"Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: Focus on Beh\u00e7et\u2019s syndrome","volume":"28","author":"Silvestri","year":"2020","journal-title":"Inflammopharmacology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients with Active Noninfectious Uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3389\/fphar.2020.00941","article-title":"Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets\u2019 Disease-Associated Uveitis: A Systematic Review and Meta-Analysis","volume":"11","author":"Hu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: Multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Beh\u00e7et\u2019s Disease: National Multicenter Study of 177 Cases","volume":"71","author":"Mesquida","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/bjophthalmol-2017-310733","article-title":"Cumulative retention rate of adalimumab in patients with Beh\u00e7et\u2019s disease-related uveitis: A four-year follow-up study","volume":"102","author":"Fabiani","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","article-title":"Ten-Year Retention Rate of Infliximab in Patients with Beh\u00e7et\u2019s Disease-Related Uveitis","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"22227","DOI":"10.1038\/s41598-020-78718-z","article-title":"A 10-year follow-up of infliximab monotherapy for refractory uveitis in Beh\u00e7et\u2019s syndrome","volume":"10","author":"Horiguchi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ophtha.2020.04.009","article-title":"Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease","volume":"127","author":"Lee","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_96","unstructured":"Liberman, P., Berkenstock, M.K., Burkholder, B.M., Chaon, B.C., and Thorne, J.E. (2020). Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation. Ocul. Immunol. Inflamm., 1\u20135."},{"key":"ref_97","first-page":"63","article-title":"Anti-tumor necrosis factor-\u03b1 agents in noninfectious uveitis","volume":"51","author":"Gueudry","year":"2012","journal-title":"Dev. Ophtalmol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09273948.2013.844265","article-title":"Long-term treatment with golimumab for severe uveitis","volume":"22","author":"Miserocchi","year":"2014","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12348-012-0081-y","article-title":"Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis","volume":"2","author":"William","year":"2012","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Behcet disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_101","first-page":"320","article-title":"Golimumab treatment for complicated uveitis","volume":"31","author":"Miserocchi","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_102","first-page":"1892.e3","article-title":"Golimumab for uveitis","volume":"118","author":"Salom","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2006.066787","article-title":"Optic neuritis occurring with anti-tumour necrosis factor alpha therapy","volume":"66","author":"Simsek","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/09273948.2010.531176","article-title":"TNF inhibitors for uveitis: Balancing efficacy and safety","volume":"18","author":"Cunningham","year":"2010","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mus.20924","article-title":"Tumor necrosis factor-alpha antagonists and neuropathy","volume":"37","author":"Stubgen","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/1352458511412996","article-title":"Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors","volume":"17","author":"Solomon","year":"2011","journal-title":"Mult. Scler. J."},{"key":"ref_108","first-page":"239","article-title":"Adalimumab-associated multiple sclerosis","volume":"34","author":"Mulleman","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ddr.21285","article-title":"Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy","volume":"76","author":"Pereira","year":"2015","journal-title":"Drug Dev. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2217\/imt.15.4","article-title":"Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: Cause for concern?","volume":"7","author":"Atzeni","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Plasencia","year":"2011","journal-title":"Rheumatology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/ICU.0000000000000210","article-title":"Local (topical and intraocular) therapy for ocular Adamantiades-Beh\u00e7et\u2019s disease","volume":"26","author":"Fabiani","year":"2015","journal-title":"Curr. Opin. Ophtalmol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajo.2012.03.035","article-title":"Intravitreal infliximab for sight-threatening relapsing uveitis in Beh\u00e7et disease: A pilot study in 15 patients","volume":"154","author":"Markomichelakis","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/IAE.0000000000001109","article-title":"Intravitreal infliximab in refractory uveitis in Behcet\u2019s Disease: A Safety and Efficacy Clinical Study","volume":"36","author":"Hamza","year":"2016","journal-title":"Retina"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Refaat, M., Abdullatif, A.M., Hamza, M.M., Macky, T.A., El-Agha, M.H., Ragab, G., and Soliman, M.M. (2020). Monthly Intravitreal Infliximab in Beh\u00e7et\u2019s Disease Active Posterior Uveitis: A Long-Term Safety Study. Retina.","DOI":"10.1097\/IAE.0000000000003095"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2009.12.011","article-title":"Intravitreal adalimumab for refractory uveitis-related macular edema","volume":"117","author":"Androudi","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_118","first-page":"319","article-title":"Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study","volume":"24","author":"Hamam","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1080\/09273948.2017.1335756","article-title":"Intravitreal Adalimumab for the Control of Breakthrough Intraocular Inflammation","volume":"26","author":"Kheir","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/jop.2010.0174","article-title":"Toxicity of high-dose intravitreal adalimumab (humira) in the rabbit","volume":"27","author":"Manzano","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00417-008-0765-z","article-title":"Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit","volume":"246","author":"Manzano","year":"2008","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00417-009-1065-y","article-title":"Evaluation of potential retinal toxicity of adalimumab (Humira)","volume":"247","author":"Tsilimbaris","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/IAE.0b013e3181e378af","article-title":"Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema","volume":"31","author":"Bae","year":"2011","journal-title":"Retina"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_125","unstructured":"(2021, February 28). Protocole National de Diagnostic et de Soins sur les Uv\u00e9ites Chroniques Non Infectieuses de L\u2019enfant et de L\u2019adulte. Available online: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-05\/pnds_ucni.pdf."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Beh\u00e7et\u2019s Disease","volume":"125","author":"Mesquida","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis","volume":"183","author":"Sepah","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/09273948.2017.1355471","article-title":"Tocilizumab for the Treatment of Beh\u00e7et Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy","volume":"26","author":"Oray","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et\u2019s disease: Multicentre retrospective study","volume":"57","author":"Atanes","year":"2018","journal-title":"Rheumatology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","article-title":"Effectiveness of tocilizumab in Behcet\u2019s disease: A systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","article-title":"Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients","volume":"200","author":"Mesquida","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","article-title":"Low immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of Gevokizumab in Patients with Beh\u00e7et\u2019s Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study","volume":"26","author":"Pavesio","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: An open-label pilot study","volume":"71","author":"Dinarello","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/09273948.2015.1092558","article-title":"Safety and Efficacy of Gevokizumab in Patients with Beh\u00e7et\u2019s Disease Uveitis: Results of an Exploratory Phase 2 Study","volume":"25","author":"Kadayifcilar","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet\u2019s disease: A case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et\u2019s disease: A multicenter retrospective study","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: A multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00296-017-3775-5","article-title":"Biological therapies for the treatment of Beh\u00e7et\u2019s disease-related uveitis beyond TNF-alpha blockade: A narrative review","volume":"38","author":"Sota","year":"2018","journal-title":"Rheumatol. Int."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: Results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","article-title":"Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Beh\u00e7et\u2019s phenotype: A multicentre study","volume":"79","author":"Fagni","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","article-title":"Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis","volume":"125","author":"Pepple","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Guillo, L., D\u2019Amico, F., Danese, S., and Peyrin-Biroulet, L. (2020). Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: A systematic literature review. J. Crohn Colitis.","DOI":"10.1093\/ecco-jcc\/jjaa260"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/ecco-jcc\/jjz167","article-title":"Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn\u2019s Disease","volume":"14","author":"Chateau","year":"2020","journal-title":"J. Crohn Colitis"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e12527","DOI":"10.1111\/dth.12527","article-title":"Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis","volume":"30","author":"Mugheddu","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/art.40912","article-title":"Long-Term Outcome of Ustekinumab Therapy for Beh\u00e7et\u2019s Disease","volume":"71","author":"Mirouse","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","article-title":"Ustekinumab for Beh\u00e7et\u2019s disease","volume":"82","author":"Mirouse","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Beh\u00e7et\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3899\/jrheum.141344","article-title":"Alemtuzumab as Remission Induction Therapy in Beh\u00e7et Disease: A 20-year Experience","volume":"42","author":"Mohammad","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"rkx004","DOI":"10.1093\/rap\/rkx004","article-title":"Short-term efficacy of abatacept in the treatment of refractory ocular and cutaneous Beh\u00e7et\u2019s disease","volume":"1","author":"Maciel","year":"2017","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et\u2019s disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"(2018). Daclizumab withdrawn from the market worldwide. Drug Ther. Bull., 56, 38.","DOI":"10.1136\/dtb.2018.4.0604"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/14656566.2017.1361408","article-title":"Small molecules as therapy for uveitis: A selected perspective of new and developing agents","volume":"18","author":"Pleyer","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Beh\u00e7et\u2019s syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_159","first-page":"53","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am. J. Ophtalmol. Case Rep."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","article-title":"Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis","volume":"27","author":"Bauermann","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et\u2019s syndrome\u2014A phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of Apremilast for Oral Ulcers in Beh\u00e7et\u2019s Syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"626792","DOI":"10.3389\/fimmu.2020.626792","article-title":"Apremilast in Refractory Beh\u00e7et\u2019s Syndrome: A Multicenter Observational Study","volume":"11","author":"Vieira","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/11\/2318\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:07:59Z","timestamp":1760162879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/11\/2318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":164,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jcm10112318"],"URL":"https:\/\/doi.org\/10.3390\/jcm10112318","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]}}}